Navigation Links
UK study: Epigenetic changes play a key role in development of chemo resistance in BCa
Date:3/18/2013

Milan, 16 March 2013 - At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer.

Neoadjuvant cisplatin-based chemotherapy is recommended for patients with muscle invasive bladder cancer. Cisplatin-based regimes have similar efficacy with complete response in 30% a survival advantage if 16% (HR, 0.84;CI 0.72 to 0.99), wrote Tan of the UCL, Dept. of Surgery and Interventional Science in London, the UK.

According to the researchers, the ability to identify a biomarker which is able to predict response to treatment would increase pathological complete response rates and spare nonresponders adverse events of chemotherapy. DNA hypermethylation has been implicated in chemotherapy resistance in cancers.

"We hypothesised that DNA methylation may not only represent the mechanisms for the acquisition of resistance, but may also be a potential biomarker to predict response to platinum based chemotherapy in bladder cancer," wrote Tan, lead author of the study titled "Epigenetic alterations associated with neo-adjuvant chemotherapy resistance in bladder cancer."

In the study, DNA was extracted from 48 muscular invasive bladder tumours, taken prior to the patient to receiving a platinum based neo-adjuvant chemotherapy, all tumours had >80% tumour content. 1ug of DNA was bisulphite converted using the EZDNA Bisulfite Conversion Kit (Zymo Research). Genome-wide DNA methylation profiles were generated using the Infinium HumanMethylation 450K BeadChip (Illumina).

According to the researchers, the analysis suggests acquired resistance is associated with global hypermethylation in both primary tumours and paired cell lines. Singular value decomposition (SVD) analysis revealed the strongest methylation signature to be associated with chemotherapy response (p=<0.001).

Supervised analysis identified ~2700 Methylation Variable Positions (MPVs) to be associated with chemotherapy response. Hierarchical clustering of the MVPs associated with chemotherapy response, defined three clusters, 1) chemo sensitive,2) chemo resistant and 3) a mixed cluster with a hypomethylation phenotype. The MVPs associated with resistance include novel genes such as MEIS2, PROM1 and MAP1LC3A, as well as genes previously associated with resistance other tumours, such as MEST and MLH1.

"These data suggest that epigenetic alterations are potential key drivers in the development of chemo resistance in bladder cancer. As well as providing novel insight into mechanisms of drug resistance, we have identified putative candidate biomarkers for further evaluation in future clinical studies, including potential stratification biomarkers in clinical trials of epigenetic therapies that reverse the acquired resistance phenotype," the researchers concluded.


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. New study: Incidence and mortality of PCa after termination of PSA-based screening
2. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
3. Omega XL Reports New Independent Study: Omega-3s Can Boost Children’s IQ
4. Study: 15% of Children Ages 10 - 14 Consider Using Steroids; polyDNA Recommends Muxscle for Safe Muscle Building
5. Study: Dynamic new software improves care of aging brain
6. Bel Marra Health Reports on a New Study: Female Obesity Could Be Due to Less Participation in Household Tasks
7. Study: Steroid Abuse in Teens is Increasing; polyDNA Recommends Muxscle for Safe Muscle Building
8. Study: Catheter-based varicose vein treatments more cost-effective
9. Penn study: Financial incentives affect prostate cancer treatment patterns
10. Study: Mega Vitamins Wont Help After Heart Attack, Chelation Treatment Might
11. Study: Diabetic medication may protect patients from developing heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... The University of San Francisco (USF) has named Margaret Wooding ... team of more than 100 full-time faculty and staff, and serve as a member ... August. , Baker comes to USF from the University of Washington in Seattle, where ...
(Date:5/25/2016)... COUNTY, FLA (PRWEB) , ... May 25, 2016 , ... ... latest technology to help turn back the hands of time of female aging. ... aging and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State College ... for their work on visual evoked potential and human attention. The article, VEP ... the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., Pine ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... has announced that it will join America's leading engineers at the American Society ... at the Georgia World Congress Center. , Engineers, speakers and exhibitors from ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... According ... found that a group of people randomly assigned to reduce the amount of calories ... a 12 percent drop in body weight enjoyed better sleep, improved quality of life, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 MedDay, ... disorders, announces that an oral presentation entitled "High doses of ... MS-SPI trial" will be given by Professor Ayman Tourbah ... 2nd Congress of the European Academy of Neurology (EAN) in ... and related disorders 3" will take place on Sunday, 29 ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: